Pharma Strategy Lookouts: Dizal Pharmaceutical, JV of AstraZeneca in China
Posted on28 Nov 2017
TagsAstraZenca, Dapagliflozin, Dizal Pharmaceutical, Farxiga, osimertinib, SGLT-2 inhibitor, Tagrisso, Type 2 Diabetes
Comments0
AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China... Read More